Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3803/EnM.2017.32.1.6 http://scihub22266oqcxt.onion/10.3803/EnM.2017.32.1.6 C5368123!5368123 !28116873     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28116873 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Endocrinol+Metab+(Seoul) 2017 ; 32 (1 ): 6-10 Nephropedia Template TP {{tp|p=28116873 |t=2017. The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis |pdf=|usr=}}{{28116873 }} gab.com Text The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis JO: Endocrinol Metab (Seoul) http://www.kidney.de/pget.php?&tw=1&pmid=28116873 #FOAvip Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed. Twit Text FOAVip The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis ????Endocrinol Metab (Seoul) http://www.kidney.de/pget.php?&tw=1&pmid=28116873 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28116873 #FOAvip English Wikipedia <ref>{{Cite pmid|28116873 }}</ref> The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis #MMPMID28116873 Moon YA Endocrinol Metab (Seoul) 2017[Mar]; 32 (1 ): 6-10 PMID28116873 show ga Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed. äThe SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis (epmc).pdf DeepDyve Pubget Overpricing